Impedimed Limited · ASX:IPD
Impedimed — 35th Annual Canaccord Genuity Growth Conference 2015
25 slides from Impedimed's conference presentation, Aug 12, 2015
Slide 1: ImpediMed to present at Canaccord Growth Conference in USA
ASX: IPD 12 Aug 2015 For personal use only ASX ANNOUNCEMENT IMPEDIMED TO PRESENT AT CANACCORD GROWTH CONFERENCE IN USA Brisbane, Australia – ImpediMed Limited (ASX: IPD) (“The Company”) today announced that Managing Director and CEO, Richard Carreon, will be presenting at the 35th Annual Canaccord G
Slide 2: 35th Annual Growth Conference
For personal use only 35th Annual Growth Conference ASX:IPD August 2015
Slide 3: Disclaimer
Disclaimer For personal use only The material contained in this document is a presentation of general information about the activities of ImpediMed Limited (“ImpediMed”) current as at the date of this presentation. The information is provided in a summary form, does not purport to be complete and sh
Slide 4: Investment Summary
Investment Summary For personal use only IPD’s bioimpedance spectroscopy (BIS) — provides a simple, non-invasive system for accurately measuring tissue composition and fluid status First product, L-Dex®, allows early identification of lymphedema — affects approximately 20% to 30% of cancer survivors
Slide 5: Corporate Overview
Corporate Overview For personal use only • ASX listed (October 2007) Share Price Performance – 12 Month (14 July 2015) • S&P/ASX 300 – added March 2015 • Operations in US (San Diego) and Aus (Brisbane) • 43 FTE staff • Market capitalization ~AU$350M (~293M shares on issue) • Cash on hand AU$32.6M (3
Slide 6: Financial Year to Date (30 June 2015)
Financial Year to Date (30 June 2015) For personal use only 30 June (preliminary and FY2015 FY2014 % Change unaudited - AUD) $000 $000 Lymphedema Revenue 2,043 1,594 28% ↑ Body Composition Revenue 968 891 9% ↑ Test & Measurement Revenue 1,832 1,036 77% ↑ Total Group Revenue 4,843 3,521 38% ↑ Operati
Slide 7: Core Technology – Simple Method for Measuring Fluid and Tissue Composition
Core Technology – Simple Method for Measuring Fluid and Tissue Composition For personal use only Bioimpedance spectroscopy — a rapid, non-invasive system that provides highly accurate data Low Frequency Fluid Unique Spectra Fat Impedance Current passes around cells High Frequency Muscle 256 Frequenc
Slide 8: Clinical Benefits Of Knowing Fluid Balance and Tissue Composition
Clinical Benefits Of Knowing Fluid Balance and Tissue Composition For personal use only • Fluid imbalance has significant clinical implications • Detailed knowledge of fluid levels are highly informative: • Chronic swelling, lymphedema, cardiovascular complications, etc. • Identify heart failure and
Slide 9: First Application – L-Dex for the Early Detection of Lymphedema
First Application – L-Dex for the Early Detection of Lymphedema For personal use only Simple and accurate measurement of fluid in limbs allows early detection and intervention 1. Treatment for cancer can damage the lymphatic system and result in fluid build up in the extremities 2. L-Dex is able to
Slide 10: A "Game Changing" Technology
A “Game Changing” Technology For personal use only • Informative – 256 frequency spectra provides detailed measurements of muscle, fluid, and fat • Simple to Use – easy placement of electrodes • Fast – 5-10 mins to measure • Non-invasive – no dyes or radiation • Safe – no safety concerns reported af
Slide 11: L-Dex Commercialisation Underway
L-Dex Commercialisation Underway For personal use only • L-Dex has regulatory approval in many major markets: • FDA clearance in US • TGA in Australia • CE Mark in Europe • Certificate of listing in Hong Kong • US Medicare reimbursement in place — L-Dex awarded a unique, dedicated CPT Category I cod
Slide 12: Potential Revenue Model for L-Dex
Potential Revenue Model for L-Dex For personal use only Annual US Relevant Cancer Incidences1 939,000 Patient Assessment Protocols (assuming US$112 per assessment - National Payment Amount) Per Patient Year 1 Year 2 Year 3 Year 4 Year 5 Total Patient 5 1-4 1-4 1-2 0-2 8 - 17 Assesments Revenue (US)
Slide 13: Cancer Center Pilots Underway
Cancer Center Pilots Underway For personal use only • Initial focus in US is on maximizing adoption by select, large, leading cancer centers • Targeted 6 major cancer center pilots over 12 months • 4 oncology and 2 multidisciplinary pilots underway • Establish best practices to maximize adoption of
Slide 14: US Targeted Launch Update
US Targeted Launch Update For personal use only Update • 6 pilots underway, (4 oncology and 2 multidisciplinary centers) • Meeting our initial launch objectives • 2 pilots will be expanding their programs to other facilities • 2 pilots have integrated L-Dex into their electronic medical records (EMR
Slide 15: L-Dex Already Incorporated into Clinical Guidelines
L-Dex Already Incorporated into Clinical Guidelines For personal use only • Key position statements on early detection of lymphedema — recommendations for BIS • Australasian Lymphology Association (ALA), Aus • National Lymphedema Network (NLN), US • National Accreditation Program for Breast Centers
Slide 16: Aim to have BIS Included In NCCN Guidelines
Aim to have BIS Included In NCCN ® Guidelines For personal use only ® NCCN Guidelines – are the recognized standard for clinical policy in cancer care in the US • Inclusion of BIS would make L-Dex the standard-of-care Recent Favorable Inclusions (First time lymphedema included in Breast Cancer Guide
Slide 17: Guidelines - Significant Opportunity
Guidelines - Significant Opportunity For personal use only Lymphedema being included in the guidelines is significant • Guidelines have now formally recognized lymphedema as a major, long- term, chronic disease that needs to be addressed • Most centers use guidelines in their care pathways • Each ce
Slide 18: Outstanding Support For Post-Market Approval Trial
Outstanding Support For Post-Market Approval Trial For personal use only • 1,100 patient multi-center, randomized controlled study (Level I Evidence) • ~25% enrolled • On track for interim data release late CY2016/early CY2017 • Early detection of lymphedema using BIS allows early treatment which pr
Slide 19: Independent Clinical Trials Also Underway/Completed
Independent Clinical Trials Also Underway/Completed For personal use only United States • 2 trials (n ~100 each site) at large teaching hospitals • Recently published 180 patient trial results — BIS reduced clinical lymphedema rate from 36.4% to 4.4% (Soran LRB2014) • Expecting second trial results
Slide 20: Platform Technology — Potential Applications and Markets
Platform Technology — Potential Applications and Markets For personal use only • BIS is a platform technology for precise measurements of tissue composition and fluid balance • Current focus is on commercialization of first product; L-Dex for early detection of lymphedema in cancer survivors • Poten
Slide 21: Strong News Flow Over Next Months
Strong News Flow Over Next 12 Months For personal use only • Regular updates on commercial usage and adoption of L-Dex • Further data from independent clinical trials • Progress on additional cancer guideline submissions • Ongoing development of new BIS opportunities • Full US commercial launch of L
Slide 22: Thank You
For personal use only Thank You
Slide 23: Appendix
For personal use only Appendix
Slide 24: Management Team Has Deep and Broad Commercialization Experience
Management Team Has Deep and Broad Commercialization Experience Rick Carreon •Joined July 2012 Managing Director and Chief •30+ years experience For personal use only Executive Officer •Extensive experience in the medical device field and growth companies •Previously Vice President at Medtronic (10
Slide 25: Board of Directors
Board of Directors Cherrell Hirst AO •On Board since 2005 For personal use only FTSE, MBBS, BEdSt, D.Univ •Appointed Non-Executive Chairman in Nov 2011 (Hon), FAICD •Leading medical practitioner in breast cancer screening/diagnosis Non-Executive Chairman •Currently interim Chairman of the Board of T
ImpediMed — 35th Annual Canaccord Genuity Growth Conference 2015 on 6ix